|
|
|
| Effect of Ulinastatin on Inflammatory Factors and Coagulation Function in Patients with Severe Sepsis |
| LUO Li, MAO Guangyu, HE Hailing |
| Xiangyang Center Hospital, Affiliated Hospital of Hubei university of Arts and Science, Hubei Xiangyang 441021, China |
|
|
|
|
Abstract Objective: To study effect of ulinastatin on inflammatory factors and coagulation function in patients with severe sepsis. Methods: 127 severe sepsis received therapy from February 2017 to February 2018 in our hospital were selected as research objects. According to the simple random grouping table, those patients were divided into the observation group (n=65) and the control group (n=62). The control group was treated with Xuebijing injection, while the observation group treated with Ulinastatin combined with Xuebijing injection. Then the Therapeutic efficacy, Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor (TNF-alpha) levels, coagulation function indicators of platelet(PLT), fibrinogen (FIB), prothrombin time (PT) and activated partial thromboplastin time (APTT), Physiology and Chronic Health Score (APACHE II) Systemic Infection Related Organ Dysfunction Score (SOFA) of two groups after treatment were compared. Results: After treatment, The total effective rate of observation group was significantly higher than that of control group [92.30%(60/65)vs74.19%(46/62)](P＜0.05). The levels of IL-6, IL-8 and TNF-alpha in the control group were significantly lower than those in the control group [(24.86±3.12)ng/L vs(61.85±5.67)ng/L,(24.16±5.80)ng/L vs(51.79±10.73)ng/L,(85.16±11.10)g/L vs(116.98±13.67 g/L)](P＜0.05). PLT, FIB was significantly higher than that of control group [(122.56±19.42)×109/L vs(88.64±13.51)×109/L,(3.06±0.61)g/L vs(2.48±0.52)g/L](P＜0.05). PT, APTT were significantly lower than those in the control group [(12.98±3.21)s vs(16.30±3.26)s, (39.75±4.26)s vs(42.95±5.08)s](P＜0.05). APACHE II and SOFA scores were significantly lower than those of the control group [(12.98±2.41) scores vs(15.87±3.05)scores,(4.29±1.40)scores vs(5.98±1.62)scores](P＜0.05). Conclusion: Ulinastatin is effective in the treatment of severe sepsis. It can effectively relieve clinical symptoms, reduce the expression of inflammatory factors, regulate coagulation dysfunction, improve prognosis, and is safe and reliable.
|
|
|
|
|
|
[1] Jorgensen A L.Nurse influence in meeting compliance with the centers for medicare and medicaid services quality measure:early management bundle,severe sepsis/septic shock(SEP-1)[J].Dimensions of critical care nursing:DCCN,2019,38(2):70.
[2] 刘文德.乌司他丁治疗重度脓毒血症患者疗效研究[J].中国现代药物应用,2015,9(15):130~131.
[3] Annane D,Mira J P,Ware L B,et al.Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis[J].Annals of Intensive Care,2018,8(1):16.
[4] 陈伟,胡志华,杨远征.乌司他丁辅助高容量血液滤过对严重脓毒血症血清细胞黏附分子-1、胆碱酯酶和凝血功能的影响[J].中国现代医学杂志,2016,26(11):54~58.
[5] 黄华庚,胡军涛.乌司他丁辅助治疗重症脓毒血症的效果及对细胞因子的影响分析[J].中外医学研究,2018,16(15):117~118.
[6] 李国保,张婕,刘志超.乌司他丁血必净联合治疗对脓毒血症凝血功能及全身炎性反应影响研究[J].中国医学工程,2016,24(12):16~18. |
|
|
|
2019, Vol. 25 
